News | March 30, 2026
Eli Lilly trial shows combo therapy dramatically improves psoriatic arthritis, obesity outcomes
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
The findings were presented as a late-breaking study at the 2026 American Academy of Dermatology
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
As Tracky launches integrated health solution
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
The milestone moves the company closer to its previously announced $120 million US expansion, with groundbreaking slated for late 2026
Subscribe To Our Newsletter & Stay Updated
